Ligands that target cannabinoid receptors in the brain

from THC to anandamide and beyond

Research output: Contribution to journalLiterature review

198 Citations (Scopus)

Abstract

A major finding-that (-)-trans-Delta(9)-tetrahydrocannabinol (Delta(9)-THC) is largely responsible for the psychotropic effects of cannabis-prompted research in the 1970s and 1980s that led to the discovery that this plant cannabinoid acts through at least two types of cannabinoid receptor, CB1 and CB2, and that Delta(9)-THC and other compounds that target either or both of these receptors as agonists or antagonists have important therapeutic applications. It also led to the discovery that mammalian tissues can themselves synthesize and release agonists for cannabinoid receptors, the first of these to be discovered being arachidonoylethanolamide (anandamide) and 2-arachidonoylglycerol. These 'endocannabinoids' are released onto their receptors in a manner that appears to maintain homeostasis within the central nervous system and sometimes either to oppose or to mediate or exacerbate the unwanted effects of certain disorders. This review provides an overview of the pharmacology of cannabinoid receptors and their ligands. It also describes actual and potential clinical uses both for cannabinoid receptor agonists and antagonists and for compounds that affect the activation of cannabinoid receptors less directly, for example by inhibiting the enzymatic hydrolysis of endocannabinoids following their release.

Original languageEnglish
Pages (from-to)147-159
Number of pages13
JournalAddiction Biology
Volume13
Issue number2
DOIs
Publication statusPublished - Jun 2008

Keywords

  • anandamide
  • cannabinoid receptors
  • cannabis
  • clinical applications of cannabinoids
  • endocannabinoid system
  • Delta(9)-tetrahydrocannabinol
  • amyotrophic-lateral-sclerosis
  • acid amide hydrolase
  • glutamatergic synaptic-transmission
  • selective inverse agonist
  • CB2 receptor
  • rat-brain
  • neuropathic pain
  • molecular characterization
  • hippocampal-neurons
  • in-vivo

Cite this

Ligands that target cannabinoid receptors in the brain : from THC to anandamide and beyond. / Pertwee, Roger G.

In: Addiction Biology, Vol. 13, No. 2, 06.2008, p. 147-159.

Research output: Contribution to journalLiterature review

@article{af3d28242f3c4f72a51f388c03948666,
title = "Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond",
abstract = "A major finding-that (-)-trans-Delta(9)-tetrahydrocannabinol (Delta(9)-THC) is largely responsible for the psychotropic effects of cannabis-prompted research in the 1970s and 1980s that led to the discovery that this plant cannabinoid acts through at least two types of cannabinoid receptor, CB1 and CB2, and that Delta(9)-THC and other compounds that target either or both of these receptors as agonists or antagonists have important therapeutic applications. It also led to the discovery that mammalian tissues can themselves synthesize and release agonists for cannabinoid receptors, the first of these to be discovered being arachidonoylethanolamide (anandamide) and 2-arachidonoylglycerol. These 'endocannabinoids' are released onto their receptors in a manner that appears to maintain homeostasis within the central nervous system and sometimes either to oppose or to mediate or exacerbate the unwanted effects of certain disorders. This review provides an overview of the pharmacology of cannabinoid receptors and their ligands. It also describes actual and potential clinical uses both for cannabinoid receptor agonists and antagonists and for compounds that affect the activation of cannabinoid receptors less directly, for example by inhibiting the enzymatic hydrolysis of endocannabinoids following their release.",
keywords = "anandamide, cannabinoid receptors, cannabis, clinical applications of cannabinoids, endocannabinoid system, Delta(9)-tetrahydrocannabinol, amyotrophic-lateral-sclerosis, acid amide hydrolase, glutamatergic synaptic-transmission, selective inverse agonist, CB2 receptor, rat-brain, neuropathic pain, molecular characterization, hippocampal-neurons, in-vivo",
author = "Pertwee, {Roger G.}",
year = "2008",
month = "6",
doi = "10.1111/j.1369-1600.2008.00108.x",
language = "English",
volume = "13",
pages = "147--159",
journal = "Addiction Biology",
issn = "1355-6215",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Ligands that target cannabinoid receptors in the brain

T2 - from THC to anandamide and beyond

AU - Pertwee, Roger G.

PY - 2008/6

Y1 - 2008/6

N2 - A major finding-that (-)-trans-Delta(9)-tetrahydrocannabinol (Delta(9)-THC) is largely responsible for the psychotropic effects of cannabis-prompted research in the 1970s and 1980s that led to the discovery that this plant cannabinoid acts through at least two types of cannabinoid receptor, CB1 and CB2, and that Delta(9)-THC and other compounds that target either or both of these receptors as agonists or antagonists have important therapeutic applications. It also led to the discovery that mammalian tissues can themselves synthesize and release agonists for cannabinoid receptors, the first of these to be discovered being arachidonoylethanolamide (anandamide) and 2-arachidonoylglycerol. These 'endocannabinoids' are released onto their receptors in a manner that appears to maintain homeostasis within the central nervous system and sometimes either to oppose or to mediate or exacerbate the unwanted effects of certain disorders. This review provides an overview of the pharmacology of cannabinoid receptors and their ligands. It also describes actual and potential clinical uses both for cannabinoid receptor agonists and antagonists and for compounds that affect the activation of cannabinoid receptors less directly, for example by inhibiting the enzymatic hydrolysis of endocannabinoids following their release.

AB - A major finding-that (-)-trans-Delta(9)-tetrahydrocannabinol (Delta(9)-THC) is largely responsible for the psychotropic effects of cannabis-prompted research in the 1970s and 1980s that led to the discovery that this plant cannabinoid acts through at least two types of cannabinoid receptor, CB1 and CB2, and that Delta(9)-THC and other compounds that target either or both of these receptors as agonists or antagonists have important therapeutic applications. It also led to the discovery that mammalian tissues can themselves synthesize and release agonists for cannabinoid receptors, the first of these to be discovered being arachidonoylethanolamide (anandamide) and 2-arachidonoylglycerol. These 'endocannabinoids' are released onto their receptors in a manner that appears to maintain homeostasis within the central nervous system and sometimes either to oppose or to mediate or exacerbate the unwanted effects of certain disorders. This review provides an overview of the pharmacology of cannabinoid receptors and their ligands. It also describes actual and potential clinical uses both for cannabinoid receptor agonists and antagonists and for compounds that affect the activation of cannabinoid receptors less directly, for example by inhibiting the enzymatic hydrolysis of endocannabinoids following their release.

KW - anandamide

KW - cannabinoid receptors

KW - cannabis

KW - clinical applications of cannabinoids

KW - endocannabinoid system

KW - Delta(9)-tetrahydrocannabinol

KW - amyotrophic-lateral-sclerosis

KW - acid amide hydrolase

KW - glutamatergic synaptic-transmission

KW - selective inverse agonist

KW - CB2 receptor

KW - rat-brain

KW - neuropathic pain

KW - molecular characterization

KW - hippocampal-neurons

KW - in-vivo

U2 - 10.1111/j.1369-1600.2008.00108.x

DO - 10.1111/j.1369-1600.2008.00108.x

M3 - Literature review

VL - 13

SP - 147

EP - 159

JO - Addiction Biology

JF - Addiction Biology

SN - 1355-6215

IS - 2

ER -